Dr. Goldberg on Further Immunotherapy Trials in Non-Small Cell Lung Cancer

Sarah Goldberg, MD, MPH, assistant professor of Medicine and Medical Oncology, Yale Cancer Center, discusses coming trials looking at immunotherapy beyond the second-line setting in non-small cell lung cancer (NSCLC). Goldberg says the most exciting part about these trial is finding out if combination immunotherapy treatment regimens could work better than single-agent regimens.

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/